{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:52:16Z","timestamp":1790301136646,"version":"4.1.0"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Diabetic nephropathy (DN), which is correlated with an increased risk of cardiovascular disease, significantly elevates the morbidity and mortality of patients with diabetes. Recently, the benefits of mineralocorticoid receptor antagonists in chronic kidney disease (CKD), such as their anti-inflammatory and anti-fibrotic properties, have been discovered. Thus, the present meta-analysis aimed to systematically assess the efficacy and safety of eplerenone treatment in patients with DN. Six electronic databases\u2014PubMed, The Cochrane Library, Embase, Web of Science, CNKI (China National Knowledge Infrastructure), and CBM(Chinese BioMedical Literature Database)\u2014were searched to retrieve randomized controlled trials that assessed eplerenone treatment in patients with DN and were published up to July 31, 2021. Eight randomized controlled trials involving 838 patients were included. Between the eplerenone treatment groups and controls, significant differences were identified in 24-h urine protein levels (mean difference [MD], \u221219.63 [95% CI, \u221223.73 to \u221215.53], <jats:italic>P<\/jats:italic> &lt; 0.00001), microalbuminuria (MD, -7.75 [95% CI, -9.75 to -5.75], <jats:italic>P<\/jats:italic> &lt; 0.00001), urinary albumin-creatinine ratio (MD, -48.29 [95% CI, -64.45 to -32.14], <jats:italic>P<\/jats:italic> &lt; 0.00001), systolic blood pressure (SBP) (MD, -2.49 [95% CI, -4.48 to -0.50], <jats:italic>P<\/jats:italic> = 0.01), serum potassium levels (MD, 0.19 [95% CI, 0.13 to 0.24], <jats:italic>P<\/jats:italic> &lt; 0.00001), and levels of the renal fibrosis indicator laminin (MD, -8.84 [95% CI, -11.93 to -5.75], <jats:italic>P<\/jats:italic> &lt; 0.00001). However, for the effect of estimated glomerular filtration rate (MD, 1.74 [95% CI, -0.87 to 4.35], <jats:italic>P<\/jats:italic> = 0.19) and diastolic blood pressure (MD, -0.51 [95% CI, -1.58 to 0.57], <jats:italic>P<\/jats:italic> = 0.36), the differences between the two groups were not significant. In addition, no noticeable difference was identified in the adverse events of hyperkalemia and cough between them. These findings suggest that eplerenone exerts beneficial effects on DN by significantly reducing urinary albumin or protein excretion, SBP, and laminin levels, without increasing the incidence of hyperkalemia and other adverse events.<\/jats:p>","DOI":"10.1371\/journal.pone.0265642","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T21:44:00Z","timestamp":1648158240000},"page":"e0265642","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy and safety of eplerenone treatment for patients with diabetic nephropathy: A meta-analysis"],"prefix":"10.1371","volume":"17","author":[{"given":"Honglei","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingqian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1975-7954","authenticated-orcid":true,"given":"Xiangguo","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"issue":"1","key":"pone.0265642.ref001","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of Type 2 Diabetes\u2014Global Burden of Disease and Forecasted Trends","volume":"10","author":"MAB Khan","year":"2020","journal-title":"J Epidemiol Glob Health"},{"issue":"8","key":"pone.0265642.ref002","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1111\/dom.14401","article-title":"Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: Insights from the DISCOVER study","volume":"23","author":"K Khunti","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"pone.0265642.ref003","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1111\/j.1523-1755.2004.00988.x","article-title":"Diabetic nephropathy: Linking histology, cell biology, and genetics","volume":"66","author":"S. Adler","year":"2004","journal-title":"Kidney Int"},{"key":"pone.0265642.ref004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-9841-8_1","article-title":"Diabetic Nephropathy: An Overview","volume":"2067","author":"MK Sagoo","year":"2020","journal-title":"Methods Mol Biol"},{"issue":"Suppl 1","key":"pone.0265642.ref005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14007","article-title":"An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines","volume":"22","author":"NM Selby","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"pone.0265642.ref006","first-page":"122","article-title":"Diabetic nephropathy and cardiovascular diseases","volume":"50","author":"S. Czekalski","year":"2005","journal-title":"Rocz Akad Med Bialymst"},{"issue":"1","key":"pone.0265642.ref007","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/bmb\/ldx047","article-title":"Managing diabetic kidney disease","volume":"125","author":"S Zac-Varghese","year":"2018","journal-title":"Br Med Bull"},{"issue":"2","key":"pone.0265642.ref008","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/ndt\/gfz290","article-title":"Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial","volume":"35","author":"HJL Heerspink","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"pone.0265642.ref009","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/dom.13987","article-title":"Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY","volume":"22","author":"JJ Rhee","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"pone.0265642.ref010","doi-asserted-by":"crossref","first-page":"16626","DOI":"10.1038\/s41598-020-73638-4","article-title":"The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial","volume":"10","author":"H Minakuchi","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"pone.0265642.ref011","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/ph14060561","article-title":"Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease","volume":"14","author":"N Vodo\u0161ek Hojs","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"pone.0265642.ref012","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"M Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"pone.0265642.ref013","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1210\/jc.2007-0393","article-title":"Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus","volume":"92","author":"HV Joffe","year":"2007","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"pone.0265642.ref014","unstructured":"Yuqiang Guo. Effect of eplerenone and spironolactone on comparison of efficacy and safety of diabetic nephropathy, Tai shan medical university; 2013."},{"issue":"002","key":"pone.0265642.ref015","first-page":"304","article-title":"Effect of Eplerenone on Microvascular Lesions and the Content of Urine Protein in Patients with Diabetic Nephropathy","volume":"33","author":"Wenjing Liang","year":"2016","journal-title":"Journal of Clinical Research"},{"issue":"4","key":"pone.0265642.ref016","doi-asserted-by":"crossref","first-page":"101190","DOI":"10.1016\/j.diabet.2020.08.005","article-title":"Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial","volume":"47","author":"NH Brandt-Jacobsen","year":"2021","journal-title":"Diabetes & metabolism"},{"issue":"6","key":"pone.0265642.ref017","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1159\/000508670","article-title":"A Prospective Single-Blind Randomized Trial of Ramipril, Eplerenone and Their Combination in Type 2 Diabetic Nephropathy","volume":"10","author":"M El Mokadem","year":"2020","journal-title":"Cardiorenal Med"},{"issue":"7","key":"pone.0265642.ref018","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3109\/10641963.2016.1151526","article-title":"Angiotensin II receptor blocker combined with eplerenone or hydrochlorothiazide for hypertensive patients with diabetes mellitus","volume":"38","author":"S Karashima","year":"2016","journal-title":"Clin Exp Hypertens"},{"issue":"S3","key":"pone.0265642.ref019","first-page":"A24","article-title":"OR-54: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone\/enalapril combination therapy in diabetic hypertensives with microalbuminuria","author":"M Epstein","journal-title":"American Journal of Hypertension"},{"issue":"Suppl 1","key":"pone.0265642.ref020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.13969","article-title":"Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets","volume":"22","author":"J Barrera-Chimal","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"pone.0265642.ref021","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic Kidney Disease: Challenges, Progress, and Possibilities","volume":"12","author":"RZ Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"pone.0265642.ref022","doi-asserted-by":"crossref","DOI":"10.1093\/ajh\/hpy120","article-title":"Mineralocorticoid Receptor and Cardiovascular Disease","author":"Buonafine Mathieu","year":"2018","journal-title":"American Journal of Hypertension"},{"issue":"36","key":"pone.0265642.ref023","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1","volume":"290","author":"L Amazit","year":"2015","journal-title":"J Biol Chem"},{"issue":"1","key":"pone.0265642.ref024","doi-asserted-by":"crossref","first-page":"199","DOI":"10.5301\/jn.5000125","article-title":"Aldosterone mediates glomerular inflammation in experimental mesangial proliferative glomerulonephritis","volume":"26","author":"D Qin","year":"2013","journal-title":"J Nephrol"},{"key":"pone.0265642.ref025","doi-asserted-by":"crossref","first-page":"661185","DOI":"10.3389\/fendo.2021.661185","article-title":"Current Challenges and Future Perspectives of Renal Tubular Dysfunction in Diabetic Kidney Disease","volume":"12","author":"S Duan","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"pone.0265642.ref026","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2215\/CJN.08350719","article-title":"Particulate Matter and Albuminuria, Glomerular Filtration Rate, and Incident CKD","volume":"15","author":"MF Blum","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"pone.0265642.ref027","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"J Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"issue":"4","key":"pone.0265642.ref028","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/jdi.12629","article-title":"Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy","volume":"8","author":"LJ Sun","year":"2017","journal-title":"J Diabetes Investig"},{"key":"pone.0265642.ref029","doi-asserted-by":"crossref","first-page":"5091951","DOI":"10.1155\/2016\/5091951","article-title":"Safety and Antihypertensive Effect of Selara\u00ae (Eplerenone): Results from a Postmarketing Surveillance in Japan","volume":"2016","author":"S Takahashi","year":"2016","journal-title":"Int J Hypertens"},{"issue":"4","key":"pone.0265642.ref030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4062\/biomolther.2020.204","article-title":"Diabetic Nephropathy\u2014a Review of Risk Factors, Progression, Mechanism, and Dietary Management","volume":"29","author":"V Natesan","year":"2021","journal-title":"Biomol Ther (Seoul)"},{"key":"pone.0265642.ref031","first-page":"e13413","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists with ACEI\/ARB treatment for diabetic nephropathy: A meta-analysis","author":"C Zuo","year":"2019","journal-title":"Int J Clin Pract"},{"issue":"3","key":"pone.0265642.ref032","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11906-019-0924-0","article-title":"Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and\/or Cost or Just a Men\u2019s Issue?","volume":"21","author":"Antonis A Manolis","year":"2019","journal-title":"Curr Hypertens Rep"},{"key":"pone.0265642.ref033","doi-asserted-by":"crossref","first-page":"647650","DOI":"10.3389\/fphar.2021.647650","article-title":"lncRNA MALAT1 Promotes Renal Fibrosis in Diabetic Nephropathy by Targeting the miR-2355-3p\/IL6ST Axis","volume":"12","author":"H Huang","year":"2021","journal-title":"Frontiers in pharmacology"},{"issue":"4","key":"pone.0265642.ref034","article-title":"Antifibrotic renal role of mineralcorticoid receptor antagonists","volume":"36","author":"A Ocello","year":"2019","journal-title":"G Ital Nefrol"},{"issue":"6","key":"pone.0265642.ref035","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1159\/000355736","article-title":"Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress","volume":"37","author":"H Chen","year":"2013","journal-title":"Kidney Blood Press Res"},{"issue":"5","key":"pone.0265642.ref036","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and\/or Chronic Kidney Disease","volume":"80","author":"N Sato","year":"2016","journal-title":"Circ J"},{"key":"pone.0265642.ref037","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2017.03.011","article-title":"True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis","volume":"188","author":"D Vukadinovi\u0107","year":"2017","journal-title":"Am Heart J"},{"issue":"3","key":"pone.0265642.ref038","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ejhf.1400","article-title":"Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial","volume":"21","author":"JP Ferreira","year":"2019","journal-title":"Eur J Heart Fail"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0265642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T21:44:46Z","timestamp":1648158286000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0265642"}},"subtitle":[],"editor":[{"given":"Muhammad Tarek","family":"Abdel Ghafar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0265642","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]}}}